Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
$13.27
-0.4%
$13.91
$6.79
▼
$41.72
$139.26M1.524,098 shs27,870 shs
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$0.92
-9.0%
$2.02
$0.90
▼
$3.23
$111.72M2.651.74 million shs3.70 million shs
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$1.96
-1.0%
$3.12
$1.32
▼
$5.08
$125.26M1.331.15 million shs1.52 million shs
OS Therapies Incorporated stock logo
OSTX
OS Therapies
$0.80
-2.1%
$1.33
$0.58
▼
$2.25
$37.04M-0.47753,364 shs489,729 shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
0.00%-0.15%+0.15%+35.69%-17.22%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
0.00%-28.20%-56.03%-60.56%-12.48%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
0.00%-10.91%-46.01%-52.20%+38.03%
OS Therapies Incorporated stock logo
OSTX
OS Therapies
0.00%+7.79%-35.76%-49.50%-51.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
$13.27
-0.4%
$13.91
$6.79
▼
$41.72
$139.26M1.524,098 shs27,870 shs
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$0.92
-9.0%
$2.02
$0.90
▼
$3.23
$111.72M2.651.74 million shs3.70 million shs
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$1.96
-1.0%
$3.12
$1.32
▼
$5.08
$125.26M1.331.15 million shs1.52 million shs
OS Therapies Incorporated stock logo
OSTX
OS Therapies
$0.80
-2.1%
$1.33
$0.58
▼
$2.25
$37.04M-0.47753,364 shs489,729 shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
0.00%-0.15%+0.15%+35.69%-17.22%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
0.00%-28.20%-56.03%-60.56%-12.48%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
0.00%-10.91%-46.01%-52.20%+38.03%
OS Therapies Incorporated stock logo
OSTX
OS Therapies
0.00%+7.79%-35.76%-49.50%-51.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
1.00
SellN/AN/A
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
2.50
Moderate Buy$5.80531.12% Upside
MacroGenics, Inc. stock logo
MGNX
MacroGenics
2.40
Hold$8.50333.67% Upside
OS Therapies Incorporated stock logo
OSTX
OS Therapies
2.75
Moderate Buy$13.331,560.44% Upside

Current Analyst Ratings Breakdown

Latest OSTX, BNR, MGNX, and FATE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
MacroGenics, Inc. stock logo
MGNX
MacroGenics
DowngradeSell (D-) ➝ Sell (E+)
11/6/2026
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Lower Price TargetEqual Weight$3.50 ➝ $3.00
11/4/2026
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Reiterated RatingSell (D-)
11/3/2026
MacroGenics, Inc. stock logo
MGNX
MacroGenics
Reiterated RatingSell (D-)
10/27/2026
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Reiterated RatingOutperform$7.00
10/23/2026
MacroGenics, Inc. stock logo
MGNX
MacroGenics
Initiated CoverageMarket Perform ➝ Positive
9/10/2026
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
UpgradeSell (E+) ➝ Sell (D-)
8/27/2026
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 11/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
$514.43M0.27N/AN/A$7.28 per share1.82
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$6.65M16.80N/AN/A$1.09 per share0.84
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$149.50M0.84N/AN/A$0.39 per share5.03
OS Therapies Incorporated stock logo
OSTX
OS Therapies
N/AN/AN/AN/A($0.37) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
-$7.92M-$0.87N/AN/AN/A-13.60%-12.98%-8.59%11/23/2026 (Estimated)
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$136.32M-$1.03N/AN/AN/A-1,941.09%-73.92%-45.16%N/A
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$74.62M-$0.81N/AN/AN/A-45.37%-246.62%-31.36%N/A
OS Therapies Incorporated stock logo
OSTX
OS Therapies
-$28.75M-$0.79N/A1.20N/AN/AN/A-544.66%N/A

Latest OSTX, BNR, MGNX, and FATE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/23/2026Q3 2026
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
-$0.3412N/AN/AN/A$19.20 millionN/A
11/16/2026Q3 2026
OS Therapies Incorporated stock logo
OSTX
OS Therapies
-$0.13-$0.23-$0.10-$0.23N/AN/A
11/5/2026Q3 2026
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$0.2701-$0.25+$0.0201-$0.25$1.14 million$1.35 million
9/10/2026Q2 2026
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
-$2.2883-$0.20+$2.0883-$0.25$19.21 million$19.84 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/AN/AN/AN/AN/A
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/AN/AN/AN/AN/A
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/AN/AN/AN/AN/A
OS Therapies Incorporated stock logo
OSTX
OS Therapies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/A
3.05
2.90
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/A
4.41
4.41
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/A
2.75
2.75
OS Therapies Incorporated stock logo
OSTX
OS Therapies
N/A
0.08
0.18

Institutional Ownership

CompanyInstitutional Ownership
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
30.03%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
97.54%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
96.89%
OS Therapies Incorporated stock logo
OSTX
OS Therapies
N/A

Insider Ownership

CompanyInsider Ownership
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
30.30%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
4.74%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
13.60%
OS Therapies Incorporated stock logo
OSTX
OS Therapies
9.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
66710.52 million7.33 millionNot Optionable
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
161121.57 million115.81 millionOptionable
MacroGenics, Inc. stock logo
MGNX
MacroGenics
29363.91 million55.22 millionOptionable
OS Therapies Incorporated stock logo
OSTX
OS Therapies
546.13 million41.70 millionN/A

Recent News About These Companies

OS Therapies (NYSEAMERICAN:OSTX) Shares Climb 9.4% - Still a Buy?
OS Therapies Notes FDA CNPV Program Suspension

New MarketBeat Followers Over Time

Media Sentiment Over Time

Burning Rock Biotech stock logo

Burning Rock Biotech NASDAQ:BNR

$13.27 -0.05 (-0.38%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$13.28 +0.02 (+0.11%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

Fate Therapeutics stock logo

Fate Therapeutics NASDAQ:FATE

$0.92 -0.09 (-9.01%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$0.96 +0.05 (+5.01%)
As of 11/20/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

MacroGenics stock logo

MacroGenics NASDAQ:MGNX

$1.96 -0.02 (-1.01%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.96 +0.01 (+0.26%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

OS Therapies stock logo

OS Therapies NYSEAMERICAN:OSTX

$0.80 -0.02 (-2.12%)
Closing price 11/20/2026 04:10 PM Eastern
Extended Trading
$0.81 +0.01 (+0.87%)
As of 11/20/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.